Media Center
Press Releases
02 Dec 13

Back to posts

Cardiovascular Disease Market: US to Lead Modest Growth, Forecasts GBI Research

The global market for Cardiovascular Disease (CVD) — comprised of Heart Failure (HF), Myocardial Infarction and Acute Coronary Syndrome (ACS) — is expected to grow at a moderate rate, from $13.7 billion in 2012 to $18.2 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 4.1%, forecasts business intelligence provider GBI Research.

The company’s latest report* states that out of the eight major markets (the US, France, Germany, Italy, Spain, UK, Japan and Canada), the US will boast the largest value, from $6.1 billion in 2012 to $8.49 billion by 2019, at a higher CAGR of 4.7%.

This growth is partially due to the increase of the treatment population, which is forecast to jump from 14 million in 2012 to 16 million by 2019, at a CAGR of 1.6%.
New drugs are also expected to have a positive impact upon the CVD market, including LCZ696 and Serelaxin by Novartis, AZD6140 by AstraZeneca and BAY81-8781 by Bayer.

Bhakti Shah, Analyst for GBI Research, says: “Over recent decades, a large amount of research and innovation has been incorporated in the cardiovascular therapeutics market segment. Of the whole pipeline, 37% of drugs are undergoing Phase II and Phase III trials. This indicates a strong pipeline capable of boosting the market in the coming years.”

However, the CVD market is hampered by high costs, with the annual cost of treatment for the three CVD indications estimated to increase from $4,214 in 2012 to $4,876 by 2019, at a CAGR of 2.1%.

“New therapy drugs, such as LCZ696 and Serelaxin by Novartis, are promising upcoming treatments that will be expensive due to their specificity. This will in turn consume a large share of patients’ healthcare expenditure, which is somewhat unavoidable,” the analyst concludes.



*Cardiovascular Diseases Therapeutics in Major Developed Markets to 2019 – Increasing Prevalence and Promising Novel Drugs offset Patent Cliff Threat

This report provides an in-depth analysis of the cardiovascular therapeutic indications, namely heart failure, myocardial infarction (MI), and acute coronary syndrome (ACS) in the eight major markets — the US, France, Germany, Italy, Spain, UK, Japan and Canada. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three cardiovascular indications.This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.


GBI Research is a market-leading provider of business intelligence reports,offering actionable data and forecasts based on the insights of key industry leaders to ensure you stayup-to-date with the latest emerging trends in your markets.

For further details, please Contact Us.

Latest Press Releases


Send this to a colleague

I have read and accept terms and conditions and privacy policy